Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Research & Development: 2019-2024

Historic Research & Development for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $19.2 million.

  • Maravai Lifesciences Holdings' Research & Development fell 18.28% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year decrease of 5.60%. This contributed to the annual value of $19.2 million for FY2024, which is 11.23% up from last year.
  • Maravai Lifesciences Holdings' Research & Development amounted to $19.2 million in FY2024, which was up 11.23% from $17.3 million recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year Research & Development high stood at $19.2 million for FY2024, and its period low was $9.3 million during FY2020.
  • Its 3-year average for Research & Development is $18.3 million, with a median of $18.4 million in 2022.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Research & Development skyrocketed by 156.52% in 2020, and later decreased by 5.93% in 2023.
  • Maravai Lifesciences Holdings' Research & Development (Yearly) stood at $9.3 million in 2020, then surged by 63.57% to $15.2 million in 2021, then rose by 20.70% to $18.4 million in 2022, then decreased by 5.93% to $17.3 million in 2023, then climbed by 11.23% to $19.2 million in 2024.